Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy最新文献

{"title":"Metformin for the Treatment of Type 2 Diabetes in Asian Adults: A Systematic Review.","authors":"Noel Somasundaram, Sanjay Kalra, Dina Shrestha, S Abbas Raza, Saptarshi Bhattacharya, Rakesh Sahay, Faria Afsana, Mohammad Wali Naseri, Guru Prasad Dhakal, Ketut Suastika, Jeyakantha Ratnasingam, Ali Abdulla Latheef","doi":"10.2147/DMSO.S479889","DOIUrl":"10.2147/DMSO.S479889","url":null,"abstract":"<p><p>Metformin is a cheap, orally administered, guideline recommended glucose-lowering drug (GLD), initiated as monotherapy in treatment naïve newly diagnosed type 2 diabetes (T2D), and in combination with other GLDs in T2D not controlled on metformin. The unique Asian T2D phenotype that is markedly different than Western population, and warrants T2D treatment approaches unique to the Asian population. However, the bulk of metformin literature is from Western population and may not be generalizable for Asians. The systematic review evaluated the efficacy and safety of metformin monotherapy and combination therapy in Asians. Literature on other GLDs recommended by the 2023 American Diabetes Association guidelines as add-on therapy to metformin were included from Asia. The systematic review concluded that metformin is effective and safe for long-term T2D control of T2D in Asians. Metformin monotherapy may be initiated and continued in treatment naïve Asian patients with T2D and/or obesity if the monotherapy is adequate for achieving glycemic control. Other GLDs may be added for better glycemic control for those who fail on monotherapy. Patients inadequately controlled on another first-line GLD can achieve glycemic control and target HbA1c of <7% by adding metformin in a once daily dose. The use of metformin reduces the risk of hypoglycemia, and its gastrointestinal side effects are mild and manageable in Asians.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"873-904"},"PeriodicalIF":2.8,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for MAFLD and Advanced Liver Fibrosis in Adult-Onset Craniopharyngioma Patients: A Cross-Sectional Study.","authors":"Lijiao Chen, Wei Wu, Hongying Ye","doi":"10.2147/DMSO.S504968","DOIUrl":"10.2147/DMSO.S504968","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the prevalence of and risk factors for metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced liver fibrosis (ALF) in postoperative adult-onset craniopharyngioma (AOCP) patients.</p><p><strong>Patients and methods: </strong>This cross-sectional study included 242 postoperative AOCP patients at Huashan Hospital (Shanghai, China). Clinical characteristics were compared between patients with and without MAFLD and ALF. Independent risk factors for MAFLD and ALF were identified using binary logistic regression analysis.</p><p><strong>Results: </strong>The prevalence of MAFLD in postoperative AOCP patients was 67.4% (95% CI 61.2-73.0%), and 32.5% (95% CI 25.8-40.0%) of patients with MAFLD were diagnosed with ALF. Body mass index (BMI) was independently associated with MAFLD (OR = 1.51, 95% CI 1.33-1.72, P < 0.001). In patients with MAFLD, hypertension (OR = 2.33, 95% CI 1.04-5.20, P = 0.040), glycated hemoglobin (HbA1c) (OR = 1.34, 95% CI 1.01-1.78, P = 0.044), daily hydrocortisone dose (OR = 1.08, 95% CI 1.01-1.15, P = 0.026), and insulin-like growth factor-1 (IGF-1)(OR = 0.99, 95% CI 0.97-0.99, P = 0.011) were independently associated with the presence of ALF.</p><p><strong>Conclusion: </strong>MAFLD is a common comorbidity in postoperative AOCP patients and is associated with a high risk of ALF. MAFLD is closely related to BMI, while ALF is significantly associated with hypertension, HbA1c levels, IGF-1 levels, and daily hydrocortisone dose. Strategies such as controlling weight gain, maintaining optimal blood glucose and blood pressure levels, appropriate hormone replacement, and avoiding excessive glucocorticoid use should be implemented to prevent and delay the onset and progression of MAFLD and ALF.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"859-871"},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Exploration of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Platelet Ratio Index (APRI) Scores with Dysglycemia and Diabetic Retinopathy: The Beichen Eye Study.","authors":"Limei Chen, Xiaoxia Miao, Manqiao Wang, Fei Gao, Emmanuel Eric Pazo, Liying Hu, Chen Chen, Yu Shi, Xiuqing Zhu, Xiaorong Li, Juping Liu","doi":"10.2147/DMSO.S502129","DOIUrl":"10.2147/DMSO.S502129","url":null,"abstract":"<p><strong>Background and purpose: </strong>Liver metabolism is closely linked to glucose levels. Studies have shown that the aspartate aminotransferase to platelet ratio index (APRI), as a marker of liver fibrosis, is associated with type 2 diabetes mellitus (T2DM). However, the existing evidence remains insufficient to establish this association definitively. Furthermore, no prior studies have investigated the potential relationship between APRI and diabetic retinopathy (DR). This study aimed to investigate the association of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to platelet ratio index (APRI) scores with dysglycemia and DR.</p><p><strong>Methods: </strong>This cross-sectional study analyzed data from 5828 participants aged 50 and older. All participants underwent laboratory blood tests, ophthalmological examinations, and interviews using questionnaires. Multiple linear regression models and receiver operating characteristic (ROC) curves explored the association between ALT and AST APRI scores and dysglycemia. Binary logistic regression was used to analyze the association between ALT and AST APRI scores and DR. Analyses were conducted for males and females separately to examine sex-specific effects.</p><p><strong>Results: </strong>In the multiple linear regression models, ALT and AST APRI scores were associated with fasting blood glucose after adjusting various potential confounders in the whole population or subgroup analysis (all P <0.05). ALT APRI score was superior to AST APRI score in the discrimination of hyperglycemic participants. In the univariate analysis, the ALT and AST APRI scores were associated with DR in the female participants with diabetes (P = 0.043, P=0.022). However, binary logistic regression models found no evident significant association between the ALT and AST APRI scores and DR in the female participants with diabetes (all P>0.05).</p><p><strong>Conclusion: </strong>ALT and AST APRI scores are potential markers for the diagnosis of hyperglycemia, and ALT APRI score is superior to AST APRI score. ALT and AST APRI scores are not independent risk factors for DR.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"847-858"},"PeriodicalIF":2.8,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951926/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes to the Haematological Parameters of Rat Offspring Born From High Fat High Carbohydrate (HFHC) Diet-Induced Prediabetic and Preeclamptic Sprague Dawley Rats: Assessing the Effects on Selected Haematological Markers.","authors":"Nombuso Xulu, Ayanda Nkosi, Andile Khathi, Ntethelelo H Sibiya, Phikelelani S Ngubane","doi":"10.2147/DMSO.S436001","DOIUrl":"10.2147/DMSO.S436001","url":null,"abstract":"<p><strong>Introduction: </strong>Infants delivered from preeclamptic pregnancies frequently exhibit developmental programming which leads to foetal growth restriction and foetal haematological abnormalities. Diabetes is recognised as a predisposing factor for preeclampsia (PE). Hyperglycaemia, a characteristic feature of pregestational type 2 diabetes, has been associated with the pathogenesis of intrauterine growth restriction (IUGR), a condition associated with disrupted foetal haematological pathways. Prediabetes pre-empts the onset of type 2 diabetes and is characterised by moderately elevated blood glucose levels, which have been shown in prediabetic models to induce erythrocyte dysfunction. However, the precise relationship between prediabetes and the development of preeclampsia or associated foetal complications remains to be fully elucidated. Accordingly, this study aims to investigate prediabetes as a risk factor for preeclampsia and its effects on selected haematological markers in Sprague Dawley rat pups.</p><p><strong>Methods and materials: </strong>Male and female pups born from normal, L-NAME preeclamptic and HFHC diet-induced prediabetic dams were immediately collected and weighed. The pups were then carefully returned to the dams for further development. On day 21, the pups were weaned and separated into males and females. Thereafter, the pups were sacrificed using a guillotine and blood and plasma was collected for haematological and biochemical analysis.</p><p><strong>Results: </strong>Pups born from prediabetic and preeclamptic dams exhibited significantly lower birth weights than those born from normal pregnancies. Moreover, pups born from prediabetic and preeclamptic dams exhibited dysregulation of red blood cell (RBC) count, granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO) levels, glutathione peroxidase (GPx) and malondialdehyde (MDA) concentrations compared to those delivered from normal dams.</p><p><strong>Conclusion: </strong>These findings suggest prediabetes caused dysregulation of haematological parameters in offspring and may be a predisposing factor for the development of preeclampsia in pregnancy. Therefore, strict monitoring of prediabetes during pregnancy may reduce the risk of preeclampsia and resultant foetal morbidity and mortality.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"831-845"},"PeriodicalIF":2.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extracellular(Serum) Levels of Matrix Metalloproteinases in Pediatric Type 1 Diabetes Mellitus and Association with Diabetic Ketoacidosis and Cerebral Edema.","authors":"Qingbo Xu, Yu Yang, Qiang Huang, Liling Xie, Yaqin Feng, Li Yang","doi":"10.2147/DMSO.S507337","DOIUrl":"10.2147/DMSO.S507337","url":null,"abstract":"<p><strong>Background: </strong>Type 1 diabetes mellitus (T1DM) in children is associated with acute complications such as diabetic ketoacidosis (DKA) and the severe risk of diabetic ketoacidosis-related cerebral edema (DKACE). Matrix metalloproteinases (MMPs) are implicated in inflammation and tissue remodeling, potentially contributing to these complications. This study explores the role of MMPs as biomarkers in pediatric T1DM patients with DKA and DKACE.</p><p><strong>Methods: </strong>We conducted a systematic cross-sectional study at Jiangxi Children's Hospital, enrolling 56 pediatric patients with T1DM, categorized into three groups: T1DM without complications, DKA, and DKACE. Serum levels of MMP-2, MMP-3, and MMP-9 were measured through ELISA. Statistical analyses assessed correlations between MMPs, glucose metabolism, and inflammatory markers, evaluating potential biomarker utility in disease characterization.</p><p><strong>Results: </strong>MMP-3 and MMP-9 levels were significantly elevated in the DKACE group compared to the T1DM and DKA groups, exhibiting strong correlations with decreased pH and bicarbonate levels (both p < 0.001). MMP-2 levels were reduced in DKACE, correlating positively with pH and bicarbonate levels. Post-clinical improvement analyses demonstrated no significant differences in MMP levels between DKA and DKACE groups, suggesting stabilization post-treatment regardless of initial acidosis severity.</p><p><strong>Conclusion: </strong>The distinct patterns of MMP-3 and MMP-9 elevations in DKACE highlight their potential as biomarkers for identifying and monitoring severe DKA complications. The findings suggest these enzymes play a significant role in cerebral edema pathophysiology, making them viable targets for future therapeutic interventions.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"819-830"},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11932032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective Effect of Semaglutide on Obesity-Induced Renal Disease and Obesity-Induced Kidney Renal Clear Cell Carcinoma.","authors":"Shuqi Wang, Mengmeng Zhang, Xiaoman Yang, Shuchun Chen","doi":"10.2147/DMSO.S498447","DOIUrl":"10.2147/DMSO.S498447","url":null,"abstract":"<p><strong>Purpose: </strong>Proteomics was used to study the effect of semaglutide on the expression of renal protein in obese mice, and looking for proteins that could improve the prognosis of Kidney Renal Clear Cell Carcinoma (KIRC).</p><p><strong>Materials and methods: </strong>Thirty-six mice were randomly divided into normal-fat diet group (NFD), high-fat diet group (HFD), high-fat diet plus semaglutide intervention group (HS). Collected mice serum, urine, kidney tissue samples, and detected urinary protein/creatinine, blood glucose, blood lipid, inflammation, oxidative stress and other related indicators. Different staining methods were used to analyze the pathological changes of mice's kidneys. Liquid chromatography-tandem mass spectrometry mass spectrometry (LC-MS/MS) analysis was used to analyze the total protein in the kidneys of mice. Finally, bioinformatics technology was used to analyze significantly different expressed proteins (DEPs).</p><p><strong>Results: </strong>The mechanism of semaglutide protecting the kidneys were related to oxidative phosphorylation, PPAR signaling pathway, thiamine, butyric acid and tryptophan metabolism pathways. Moreover, semaglutide could significantly increase the expression of Man1a1 and Ntn4 in the kidneys of mice, while the high-expression of Man1a1 and Ntn4 in KIRC population had a better overall survival rate.</p><p><strong>Conclusion: </strong>Semaglutide could regulate the development of KIRC by up-adjusting the expression of Man1a1 and Ntn4.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"805-818"},"PeriodicalIF":2.8,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Effects of Glucagon-Like Peptide-1 Receptor Agonists Compared to Long-Acting Insulin, Added to Oral Anti-Diabetic Agents on Self-Management Behaviors, Anxiety, and Sleep Quality in Patients with Type 2 Diabetes.","authors":"Xiaoqing Song, Xueke Yang, Qinghua Liu, Xuna Bian, Lianlian Gao, Jing Tao","doi":"10.2147/DMSO.S502475","DOIUrl":"10.2147/DMSO.S502475","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to investigate the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on individuals with type 2 diabetes (T2DM) by comparing self-management behaviors, anxiety, and sleep quality in T2DM patients.</p><p><strong>Methods: </strong>This is a single-center prospective study. During the patients' hospitalization, we collected their clinical data, and three months after discharge, we conducted follow-up by phone to record weight changes, blood glucose levels, self-management behaviors, anxiety levels, and sleep quality.</p><p><strong>Results: </strong>A total of 271 patients were included in this study. Among them, 177 (65.31%) were classified into the oral drug combined with long-acting insulin group, and 94 (34.69%) were classified into the oral drug combined with GLP-1RAs group. No statistically significant differences were found between the two groups in age, duration of diabetes, comorbidities, complications, or types of oral medications (P> 0.05). However, significant differences were observed between the groups in postprandial blood glucose, glycated hemoglobin, dietary control, medication adherence, actual anxiety, and sleep time (P<0.05). Notably, the oral medication combined with GLP-1RAs group demonstrated improved dietary control, medication adherence, anxiety and actual sleep time compared to the oral medication combined with long-acting insulin group.</p><p><strong>Conclusion: </strong>In this 3-month study, there were statistically significant differences in HbA1c, post-prandial glucose, weight, for self-management behaviors, for dietary control, medication adherence, anxiety, and actual sleep time in T2DM patients. The findings suggest that GLP-1 RA may contribute to the improvement of dietary behaviors, medication adherence, anxiety, and sleep quality in addition to weight and glycemic control in T2DM patients.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"795-803"},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma Fetuin-B Levels are Associated with Nervous Symptoms and Conduction Velocity in Patients with Painful DPN.","authors":"Ke Lin, Xiaocui Wang, Tao Gu, Keduo Feng, Wang Zeng, Liu Yang","doi":"10.2147/DMSO.S485853","DOIUrl":"10.2147/DMSO.S485853","url":null,"abstract":"<p><strong>Aim: </strong>To assess the plasma concentrations of the novel hepatokine fetuin-B in individuals with type 2 diabetes with or without diabetic peripheral neuropathy (DPN), and to evaluate the relationship among fetuin-B levels, nervous function, and metabolic parameters.</p><p><strong>Methods: </strong>A total of 333 participants were recruited and divided into three groups: DPN, painful DPN (pDPN), and non-DPN. Metabolic parameters, peripheral neuropathy-associated indices, and general biochemical parameters were also measured.</p><p><strong>Results: </strong>Compared with the non-DPN group, general parameters, including age, SBP, BUN, Cr, and ALT, were significantly higher in the DPN and pDPN groups, and FPG, HbA1c, TC, TG, LDL, BUN, Cr, and UA levels were higher in the pDPN group. The neuropathy symptom score (NSS), neuropathy disability score (NDS), and Douleur Neuropathique en 4 Questions (DN4) were highest in the pDPN group, followed by the DPN group, and lowest in the non-DPN group. Moreover, fetuin B levels showed the same trends as peripheral neuropathy indices. Additionally, oxidative stress markers showed a decrease in total antioxidant capacity (TAC) and an increase in malondialdehyde (MDA) across all groups, with the most pronounced changes observed in pDPN patients. Bivariate correlation analysis showed that fetuin B levels were positively correlated with FPG, TC, LDL, NSS, NDS, DN4, and MDA levels, and negatively associated with TAC after adjusting for age and sex. Furthermore, nerve conduction velocity, including MLT, MRT, SRS, and SLT, showed decreasing trends among tertiles of fetuin B levels.</p><p><strong>Conclusion: </strong>The current study suggests that circulating fetuin-B levels may be associated with the progression of pDPN and highlights the effects of hepatokine-mediated liver-to-peripheral nervous system crosstalk in DPN.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"785-793"},"PeriodicalIF":2.8,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11913742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Prediction Model for Arteriovenous Fistula Maturation Failure in Elderly Diabetic Patients: Limitations and Future Directions [Response to Letter].","authors":"Shuangyan Liu, Xiaojie He, Yaqing Wang, Yuqing Wang, Xiaodong Li","doi":"10.2147/DMSO.S525796","DOIUrl":"10.2147/DMSO.S525796","url":null,"abstract":"","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"781-783"},"PeriodicalIF":2.8,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11912932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Metabolic Score for Visceral Fat (METS-VF) with Gout Risk in Patients with Hypertension and Hyperuricemia: A Multicenter Study Based on the Chinese Population.","authors":"Liwei Ji, Wencai Jiang, Jinglin Huang, Yan Xu, Li Zhou, Zeng Zhao, Chunling Jiang","doi":"10.2147/DMSO.S502675","DOIUrl":"https://doi.org/10.2147/DMSO.S502675","url":null,"abstract":"<p><strong>Background: </strong>Gout, a rheumatic disease precipitated by hyperuricemia, has become a global health concern due to its increasing prevalence, especially in China. Hyperuricemia and hypertension are significant risk factors for gout, and their coexistence amplifies this risk. Visceral adipose tissue (VAT) plays a crucial role in cardiometabolic diseases, and the metabolic score for visceral fat (METS-VF) is a non-invasive tool for estimating VAT and predicting cardiometabolic risk.</p><p><strong>Methods: </strong>We conducted a multicenter cross-sectional study involving 8877 patients with hypertension and hyperuricemia from three Chinese medical centers between March 2021 and September 2024. We calculated the METS-VF and other obesity indices and analyzed their associations with gout risk using logistic regression models. The predictive performance of these indices was evaluated using receiver operating characteristic (ROC) curve analysis and clinical decision curve analysis (DCA).</p><p><strong>Results: </strong>The METS-VF demonstrated a significant positive association with gout risk, independent of traditional risk factors. Each 1-standard deviation increase in the METS-VF was associated with an 82% higher odds of gout (OR=1.82, 95% CI: 1.62 to 2.03). The METS-VF outperformed other obesity indices in predicting gout risk, with a higher area under the ROC curve (AUC) value. DCA indicated that the METS-VF provided a significant net benefit across a wide range of threshold probabilities for predicting gout risk in both genders.</p><p><strong>Conclusion: </strong>The METS-VF's robust association with gout risk in our multicenter study, independent of conventional risk factors, positions it as a potent predictor for gout. Further investigation is warranted to clarify the underlying mechanisms and the long-term predictive validity of the METS-VF across diverse populations.</p>","PeriodicalId":11116,"journal":{"name":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy","volume":"18 ","pages":"761-779"},"PeriodicalIF":2.8,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}